Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2014 May;25(5):1547-54.
doi: 10.1007/s00198-014-2635-3. Epub 2014 Feb 22.

Comparison of two commercially available ELISAs for circulating sclerostin

Affiliations
Comparative Study

Comparison of two commercially available ELISAs for circulating sclerostin

A G Costa et al. Osteoporos Int. 2014 May.

Abstract

This study investigates the performance and correlation of sclerostin measurements by two commercially available sclerostin ELISAs from TECOmedical and Biomedica. We found that the correlation between the results of two sclerostin assays is strong.

Introduction: Circulating sclerostin levels may provide insight into the pathophysiology of metabolic bone diseases such as osteoporosis. However, recent studies suggest that commercially available assays give different results. We compare the analytical performance of the two most used commercially available sclerostin ELISAs from TECOmedical and Biomedica.

Methods: Sclerostin levels were assessed in 20 paired serum, EDTA, and heparin plasma convenience samples from hospitalized patients. In addition, sclerostin was measured in serum samples from 34 patients with metabolic bone diseases and from 10 patients with chronic kidney disease (CKD). Samples from three healthy donors were used to determine stability and intra- and inter- assay precision.

Results: The average serum sclerostin concentration of all patients (n = 64) was 0.713 ± 0.58 ng/mL with the Biomedica assay and 0.734 ± 0.43 ng/mL with the TECO assay (p < 0.05). The results correlated strongly (r = 0.9; p < 0.0001), with Passing-Bablok regression showing a linear relationship but with a slight systematic and proportional difference between both assays. Sclerostin levels were about 30% higher in plasma than in serum for both assays, while no significant difference was seen between EDTA and heparin plasma. Intra- and inter- precision were <10% for TECO and <20% for Biomedica. Samples were stable for up to three freeze-thaw cycles with both assays.

Conclusions: The two commercially available ELISAs for measuring circulating levels of sclerostin are comparable. However, given the small but statistically significant systematic and proportional differences between both assays, results and reference ranges will be assay-specific. Results will also be specific to serum or plasma.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Osteoporos Int. 2013 Feb;24(2):489-94 - PubMed
    1. J Clin Endocrinol Metab. 2011 Jul;96(7):E1159-62 - PubMed
    1. Bone. 2013 Oct;56(2):355-62 - PubMed
    1. Horm Metab Res. 2012 Nov;44(12):909-13 - PubMed
    1. J Clin Endocrinol Metab. 2010 Nov;95(11):5056-62 - PubMed

Publication types

LinkOut - more resources